← Leaderboards
Katherine Elena Varley
University Of Utah
$4,277,906
Attributed
$7,610,102
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2016–24$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,610,102 · 3
By mechanism
U01$4,226,076 · 1
R01$2,354,401 · 1
UH3$1,029,625 · 1
Top collaborators
- Gabor T Marth5 shared
- Bryan E. Welm5 shared
- Philip S Bernard3 shared
Most similar at University Of Utah
Same institution · by research overlap
- William L. Carroll$23,653,738
- Mary C. Beckerle$16,693,203
- Kathleen H Mooney$23,401,107
- Sally Ozonoff$24,108,835
- Susan L. Neuhausen$19,099,097
Others in their field
Top investigators on “Specimen”
- Jeffrey P Krischer · University Of South Florida$372,057,923
- Marian Ewell · The Emmes Company, Llc$278,931,253
- David Heimbrook · Leidos Biomedical Research, Inc.$273,257,812
- James Dennis Neaton · Northwestern University$273,164,823
- Judith S. Currier · University Of California Los Angeles$170,089,509
- Barbara Driver · Westat, Inc.$161,528,142
Research focus
SpecimenMalignant Breast NeoplasmTumorSamplingBreast Cancer PatientDna MethylationIndividual PatientGenomicsFrequenciesMolecularMutationNeoadjuvant TherapyMammary NeoplasmsPatient CareGene ExpressionSpecificityReportingClia CertifiedResearch Clinical TestingBiological MarkersOncologistLaboratoriesRecurrenceDiagnosis
Grant awards (13)
Validation of the MHC II Immune Activation Assay in Breast Cancer$333,931
UH3 · FY2024 · CA · contact PI
Validation of the MHC II Immune Activation Assay in Breast Cancer$344,474
UH3 · FY2023 · CA · contact PI
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$806,283
U01 · FY2022 · CA
Validation of the MHC II Immune Activation Assay in Breast Cancer$351,220
UH3 · FY2022 · CA · contact PI
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$812,870
U01 · FY2021 · CA
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$986,128
U01 · FY2020 · CA
A partnership to enable clinical ctDNA testing for breast cancer recurrence$472,123
R01 · FY2020 · CA · contact PI
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$798,057
U01 · FY2019 · CA
A partnership to enable clinical ctDNA testing for breast cancer recurrence$457,959
R01 · FY2019 · CA · contact PI
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$822,738
U01 · FY2018 · CA
A partnership to enable clinical ctDNA testing for breast cancer recurrence$472,123
R01 · FY2018 · CA · contact PI
A partnership to enable clinical ctDNA testing for breast cancer recurrence$470,203
R01 · FY2017 · CA · contact PI
A partnership to enable clinical ctDNA testing for breast cancer recurrence$481,993
R01 · FY2016 · CA · contact PI